Publications & Posters

KemPharm® believes that its LAT™ Platform technology offers potential benefits to improve drug properties by developing prodrugs that are new molecules with improved attributes over FDA-approved drugs, such as enhanced bioavailability, extended duration of action, increased safety, and reduced susceptibility to abuse.


Poster Presentations

American College of Neuropsychopharmacology – December 9-13, 2018

American Academy of Child & Adolescent Psychiatry – October 22-27, 2018

American Professional Society for ADHD and Related Disorders – January 12-14, 2018

2017 International Conference on Opioids (ICOO) – June 11-3, 2016

American Academy of Pain Medicine (AAPM) Annual Meeting – March 15-19, 2017

2016 International Conference on Opioids (ICOO) – June 5-7, 2016